Triple Therapy For H Pylori

28 October 1996

- A triple therapy regimen for Helicobacter pylori eradication, based on a low dose of Astra's Losec (omeprazole; 20 mg/day), a standard dose of Abbott's Biaxin (clarithromycin; 500mg tid) and amoxicillin 1,000mg bid), is more effective than the approved dual regimen using 40mg/day omeprazole and clarithromycin, according to data presented at the European H pylori study group meeting on October 18. The new 10-day regimen, called ACT-10, might also permit cost savings, and has the advantage of not using metronidazole, which has a high rate of resistance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight